Oncology
How quality of life can drive equitable cancer care and outcomes
Health inequalities are increasingly evident and affect more people …
19794 items found
News
Beam cuts one in five staffers to conserve cash
Gene-editing company Beam Therapeutics has shifted into reverse, …
R&D
One Health: The interconnection of animal and human health
There’s a tendency to overlook the fact that human health and animal …
R&D
Partner Content
5th RNAi-Based Therapeutics Summit
Despite exciting advancements and new investments into the field, the …
R&D
Partner Content
DNA Process Development & Manufacturing Summit
With the cell and gene therapy industry surging, rapid advances in …
News
£30m scheme to find new antimicrobials launches in UK
The UK has launched a programme to try to accelerate the discovery …
News
Pfizer sets Paxlovid price at nearly $1,400 per course
Pfizer has revealed what it will charge for a five-day course of its …
Digital
Sponsored
How AI can bolster each step of the clinical trial journey
New technologies are bringing into effect rapid change across the …
News
Lilly makes another ADC play, buying Mablink
Eli Lilly has agreed a deal to acquire French antibody-drug conjugate …
Digital
How generative AI Is transforming healthcare
With growing digitisation, there’s no shortage of information you can …
Patients
Balancing the health ecosystem: Putting the patient first
In March 2023, Roz Bekker was appointed managing director of Janssen …
News
Chan Zuckerberg Initiative to put $250M into new NYC Biohub
The Chan Zuckerberg Initiative is launching a new Biohub, its third, …
News
Journey slips on FDA approval of rosacea therapy
Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder.
Digital
Sponsored
The AI effect in pharma commercial strategy: From data to re...
Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
Sales & Marketing
Deep Dive: Commercialisation 2024
In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
Sales & Marketing
Sponsored
Seeking a single source of truth: Standardisation of the dat...
Oskar Mӧbert, Vice President of OpenData at Veeva Systems, spoke with Ian Cornish, Associate Director of Data Platforms at Astellas, about the company’s decision to opt into Veeva’s OpenDat
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
R&D
Partner Content
EHS&S for Biopharma & Pharma Summit
Implementing Corporate & Regulatory-Guided EHS Practices to Achieve Zero Biosafety, Ergonomic & Chemical Incidents for Employee Safety Across Global Facilities
R&D
Partner Content
Proteomic Based Drug Discovery Summit 2025
Determine Optimum Application of Proteomics to Accelerate Screening of Novel Targets, Unravel the Mode of Action, & Identify Biomarkers to Progress Small Molecule Drug Discovery & T
